Vidofludimus calcium

None\n Welcome to this week\'s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia or Zoey Becker and it will be featured here at the end of each week.Astellas appoints new top strategist from Sanofi JapanAstellas Pharma After last month’s departure of longtime executive Adam Pearson, Astellas has picked out a new strategist to fill the open spot on its C-suite with Takahiko Iwaya, who takes over as chief strategy officer on July 1. Before embarking on a career within biopharma leadership, Iwaya joined what is now Japan’s Ministry of Health, Labour and Welfare in 1990, where he worked on healthcare systems and policies for 14 years. After that, the executive held various leadership positions at Johnson & Johnson Japan before joining Sanofi’s Japan unit in 2019. In June, the executive will step down from his current role as president and representative director at Sanofi Japan, as well as depart his role as chair of the European Federation of Pharmaceutical Industries and Associations, Japan. He takes over the strategy role at Astellas from Peter Sandor, M.D., who has been holding down the fort on an interim basis since Pearson’s resignation. ReleaseImmunic preps for approval push with pharma vetImmunicAs a critical phase 3 readout for its multiple sclerosis candidate rapidly approaches, Immunic is shoring up its leadership with Michael Panzara, M.D., as chief medical officer. Panzara previously oversaw the approvals of other MS medicines like Biogen’s Tysabri and Sanofi’s Lemtrada and Aubagio. Panzara takes over for the departing Andreas Muehler, M.D., who is also a co-founder of Immunic. Immunic’s vidofludimus calcium is currently being tested in a pair of phase 3 trials, though the candidate previously failed to hit the primary endpoint of a phase 2 study. ReleaseCardiologist turns new leaf at NuevocorNuevocorCardio-focused Nuevocor is making a hearty change to its C-suite, bringing in experienced cardiologist Monica Shah, M.D., as chief medical officer. Shah brings a wealth of cell and gene therapy experience, including stints leading the global AAV program at Rocket Pharmaceuticals and the cell and gene therapy division of IQVIA. She built her career with a nearly nine-year tenure at the National Institutes of Health, mostly as the deputy chief of heart failure and arrhythmias at the National Heart, Lung, and Blood Institute. Nuevocor is counting on Shah to guide first-in-human studies of NVC-001, the biotech’s lead gene therapy for cardiomyopathy. Release> AI-focused vaccine maker Evaxion is opting for a dual role for chief scientific officer Birgitte Rønø, who has now been promoted to chief operating officer as well. Release> Convergent Therapeutics is bringing in seasoned dealmaker Andrew Davis to serve as chief business and strategy officer. Release> Longtime CEO Eric Goupil is handing over the reins at global contract manufacturer Unither Pharmaceuticals, with Henrik Krüpper lined up to take his place on May 4. Release> Hot off a deal with Merck & Co., antibody outfit Infinimmune is upping its pipeline tactics with Anthony Slavin, Ph.D., as senior vice president of portfolio strategy. Release> British cell and gene CDMO eXmoor Pharma is welcoming former Catalent CEO George Fotiades as chair, while founder Angela Osborne steps back from the role. Release> Synthetic biology specialist Manus Bio has named Baljit Ghotra, Ph.D., as senior vice president of innovation and operations. Release

NEW YORK, April 30, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13: 26th Bio€quity Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in Prague, Czech Republic and virtually. To schedule a meeting, please use the Bio€quity Europe conference portal or contact Jessica Breu at: [email protected]. May 27-29: 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in Charlotte, NC. One late-breaking poster and two additional posters have been accepted for presentation and will be accessible on the "Events and Presentations" section of Immunic's website at: . Additionally, the team will be available throughout the event at booth #307. Late-Breaking Poster Presentation: Title: Novel Unified Statistical Analyses for Confirmed Disability Changes In Multiple Sclerosis for Capturing Possible Neuroprotective Effects Presenting Author: James Myles, Global Head of Biostatistics at Immunic Abstract ID: 11244 Poster Board Label: LBA14 Session Date: Thursday, May 28, 2026 Session Time: 5:00-7:00 pm ET Location: Exhibit Hall Poster Presentations: Title: Effect of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor, on Patient-Reported Outcomes (PRO) in Progressive MS: Data from Phase 2 CALLIPER Trial Presenting Author: Julie Korich, Ph.D., Senior Medical Director, Medical Affairs at Immunic Abstract ID: 10843 Poster Board Label: DMT10 Session Date: Thursday, May 28, 2026 Session Time: 5:00-7:00 pm ET Location: Exhibit Hall B Title: Safety and Tolerability of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor: Data from Phase 2 CALLIPER Trial Presenting Author: Alex Lublin, Ph.D., Senior Medical Director, Medical Affairs at Immunic Abstract ID: 10995 Poster Board Label: DMT11 Session Date: Thursday, May 28, 2026 Session Time: 5:00-7:00 pm ET Location: Exhibit Hall B About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: . Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and medical conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, Inc. Jessica Breu Vice President Investor Relations and Communications +49 89 2080 477 09 [email protected] US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 [email protected] US Media Contact KCSA Strategic Communications Caitlin Kasunich +1 212 896 1241 [email protected] SOURCE Immunic, Inc. 21% more press release views with Request a Demo